The orforglipron weight loss pill is Eli Lilly's once-daily oral GLP-1. In its phase 3 obesity trial, the highest dose produced an average weight loss of 27.3 pounds or 12.4 percent of body weight, over 72 weeks. That is a real, meaningful result. It lands below what injectable tirzepatide achieves on average and most people are asking about exactly that comparison. If you want a GLP-1 without injections, here is what the pill has shown, what it costs, who it fits and how we prescribe it.
- Orforglipron is a once-daily oral GLP-1 pill, taken with nothing else in the stomach, no injection and no food timing rules.
- In the phase 3 ATTAIN-1 trial the highest dose produced an average 12.4 percent weight loss at week 72, published in the New England Journal of Medicine.
- Injectable tirzepatide showed up to about 22.5 percent average weight loss in its own registration trial, so the pill trades some efficacy for convenience.
- The pill is taken at a fixed dose without dose escalation by design, which fits a flat-fee model where the bill never climbs with the prescription.
- We prescribe branded and FDA-approved medication only, at pharmacy cost with zero markup, whichever molecule the patient and the data choose.
What the pill actually is
Orforglipron is a small-molecule GLP-1 receptor agonist, which is a technical way of saying it works through the same appetite and metabolic pathways as the injected drugs but survives being swallowed. Injectable GLP-1s are peptides that digestion destroys, so they are given by needle. Orforglipron is engineered to survive the gut, which is why a pill form is possible at all. It is taken once daily with water, on an empty stomach, without the two-hour fasting window older oral GLP-1s required.
The practical appeal is obvious and we do not talk patients out of it. A large share of people who want this treatment category will never start it as a weekly or daily injection and a pill that gets a serious result is worth more to that person than a slightly bigger result they will never begin.
What the phase 3 trial showed
ATTAIN-1 enrolled adults with obesity or overweight plus a weight-related condition and its results were published in the New England Journal of Medicine in September 2025. At 72 weeks the highest studied dose, 36 mg, produced a mean weight reduction of 27.3 pounds against placebo. Roughly half of participants on the highest dose lost at least 10 percent of their body weight, around a third lost at least 15 percent and nearly one in five lost at least 20 percent. Triglycerides, non-HDL cholesterol and blood pressure also improved. The most common side effects were gastrointestinal and discontinuation for them ran in the single digits, consistent with the injected drugs.
For comparison, SURMOUNT-1 showed an average weight loss up to about 22.5 percent on injectable tirzepatide and STEP-1 showed about 15 percent on semaglutide. Those are trial averages across different populations and protocols, not a head-to-head and individual results vary widely in every study. The honest summary is that the pill sits in the same category with a somewhat smaller average result and no needle.
Oral orforglipron against the injected GLP-1s
| Medication | Form | Average weight loss in registration trial |
|---|---|---|
| Orforglipron 36 mg | Daily pill | About 12.4 percent at 72 weeks |
| Semaglutide (Wegovy) | Weekly injection | About 15 percent |
| Tirzepatide (Zepbound) | Weekly injection | Up to about 22.5 percent |
The honest tradeoff
Two tradeoffs sit in front of anyone choosing between the pill and the injections. The first is efficacy. If the goal is the largest average reduction the category can deliver, tirzepatide holds that position and the pill does not match it. If the goal is a meaningful, durable result in a form you will actually take every day, the pill's 12 percent average is nothing to dismiss.
The second tradeoff is dosing structure and it is where the economics get interesting. Orforglipron is taken at a fixed dose without dose escalation by design. Injected GLP-1s titrate through dose steps and much of the industry monetizes that ladder, pricing each step higher. A molecule with a flat dosing profile cuts the staircase out of the business model entirely. We describe this in why GLP-1 prices escalate with dose, because it is one of the clearest cases where the science and the revenue model point in opposite directions.
What the pill costs
Orforglipron pricing is still moving as launch proceeds and we will not quote a number we cannot verify. What we can state plainly is our structure. Under our membership, every prescription is billed directly by your pharmacy at pharmacy cost, with zero markup, no molecule upcharge and no dose-escalation fee, whichever molecule you end up on. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger.
That structure answers the objection we hear from the stability-minded patient most often, which is the fear of a bill that climbs as the prescription does. With us the membership is a flat $299 per month and the medication invoice is the pharmacy's cost, so if the pill or any other molecule changes price, you see the raw change rather than a platform padding on top of it.
Who the pill fits and who should consider injections
A pill fits the patient who will start tomorrow with a tablet and never start with a needle. It fits the traveler, the needle-averse and anyone whose life is simpler on a tablet in the morning. It also fits the patient who wants a fixed dose without a titration calendar.
Injections fit the patient whose priority is the largest average result or who has already tried lower-efficacy tools and needs the strongest lever available. Semaglutide in tablet form is another oral option for some patients, which we compare in Wegovy Tablets versus injections. The right answer comes out of your history, your labs and an honest conversation with the clinician, not out of an internet quiz.
What we do not do
We do not prescribe compounded copies of GLP-1 medication, under any circumstance and we explain why for anyone weighing a cheaper vial. When a new molecule like orforglipron arrives, it enters our protocols as branded, FDA-approved product dispensed through licensed pharmacies, nothing else. The chemistry being new is exactly why the proven product matters.
How a decision like this actually gets made
Molecule choice is a clinical decision that runs on three inputs. First, your history, including your weight trajectory, metabolic labs, GI tolerance and what you have already tried. Second, your goals, which include the number on the scale and everything around it, from muscle retention to cardiovascular risk. Third, your real life, which includes the form factor you will actually sustain and the price you are choosing to pay. Our membership is built so those three inputs meet a clinician who has no financial stake in the answer.
If you want that conversation with a physician who reads your biomarkers rather than a quiz that prints a prescription, check your eligibility or read what our medical weight loss program includes.
FAQ
What is orforglipron? It is Eli Lilly's once-daily oral GLP-1 receptor agonist, a small-molecule pill that works through the same appetite and metabolic pathways as injectable GLP-1 medications without requiring an injection.
How much weight can you lose on orforglipron? In the phase 3 ATTAIN-1 trial the highest dose produced an average loss of 27.3 pounds or 12.4 percent of body weight, over 72 weeks. Individual results vary widely and averages from trials are not a forecast for any person.
Is orforglipron FDA approved? Its approval status is moving through the regulatory process and we do not prescribe unapproved products. Where prescribing is not yet available, our protocols offer the approved branded alternatives, including Wegovy, Zepbound, Ozempic, Mounjaro and Wegovy Tablets.
Is orforglipron better than Ozempic or Wegovy? Different form, different average result. The pill showed about 12.4 percent average weight loss while injectable semaglutide showed about 15 percent and injectable tirzepatide up to about 22.5 percent in their registration trials. The right choice depends on your goals, your tolerance and which form you will actually take.
Does orforglipron have side effects? The most common are gastrointestinal, meaning nausea, diarrhea or constipation, consistent with the injected GLP-1s. In the phase 3 trial discontinuation for side effects ran in the single digits. A clinician manages these with food structure and dose decisions, which is part of what supervision is for.
How much does orforglipron cost? Pricing is still settling as launch proceeds. Under our membership any prescription is billed directly by your pharmacy at cost with zero markup from us and the membership fee of $299 per month never changes with the molecule or the dose.
Do you prescribe compounded GLP-1 pills? Never. Compounded GLP-1 is not prescribed under our clinical protocols in any form. Only branded, FDA-approved medication is used, dispensed through licensed pharmacies.
Related Reading
- GLP-1 pill vs injection: the honest comparison
- Wegovy Tablets versus injections
- Compounded versus branded GLP-1
- Medical weight loss at GoodLife Health
References
- Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity (ATTAIN-1, New England Journal of Medicine, 2025). 2025. www.nejm.org/doi/full/10.1056/NEJMoa2511774
- Eli Lilly: complete ATTAIN-1 results of orforglipron, mean weight loss 27.3 lbs (12.4%) at the highest dose at week 72. 2025. lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight